The early years of retroviral protease crystal structures.
Soon after its discovery, the attempts to develop anti-AIDS therapeutics focused on the retroviral protease (PR)-an enzyme used by lentiviruses to process the precursor polypeptide into mature viral proteins. An urgent need for the three-dimensional structure of PR to guide rational drug design prompted efforts to produce milligram quantities of this enzyme. However, only minute amounts of PR were present in the HIV-1 and HIV-2 viruses, and initial attempts to express this protein in bacteria were not successful. This review describes X-ray crystallographic studies of the retroviral proteases carried out at NCI-Frederick in the late 1980s and early 1990s and puts into perspective the crucial role that the total protein chemical synthesis played in unraveling the structure, mechanism of action, and inhibition of HIV-1 PR. Notably, the first fully correct structure of HIV-1 PR and the first cocrystal structure of its complex with an inhibitor (a substrate-derived, reduced isostere hexapeptide MVT-101) were determined using chemically synthesized protein. Most importantly, these sets of coordinates were made freely available to the research community and were used worldwide to solve X-ray structures of HIV-1 PR complexes with an array of inhibitors and set in motion a variety of theoretical studies. Publication of the structure of chemically synthesized HIV-1 PR complexed with MVT-101 preceded only by six years the approval of the first PR inhibitor as an anti-AIDS drug.
Miller
Maria
M
Protein Structure Section, Macromolecular Crystallography Laboratory, NCI-Frederick, Frederick, MD 21702-1201, USA. mariami@mail.nih.gov
D018360:Crystallography, X-Ray / Q000266:history; D016333:HIV Protease / Q000737:chemistry* / Q000266:history; D017320:HIV Protease Inhibitors / Q000737:chemistry / Q000266:history; D015497:HIV-1 / Q000201:enzymology*; D015498:HIV-2 / Q000201:enzymology*; D049673:History, 20th Century; D009842:Oligopeptides / Q000737:chemistry / Q000266:history; D017434:Protein Structure, Tertiary; D013329:Structure-Activity Relationship
D017320:HIV Protease Inhibitors; D009842:Oligopeptides; C061946:MVT 101; D016333:HIV Protease